Published Study Validates Agendiaโs MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Researchers Conclude Molecular Test Is Able to Differentiate High and Read More
Researchers Conclude Molecular Test Is Able to Differentiate High and Read More
Next-Generation Genomic Tests Determine Molecular Subtypes and Risk of Recurrence, Read More
Podium Presentations and Ten Scientific Posters Focus Cancer MDsโ Attention Read More
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Read More
Important Role of Molecular Subtyping in Determining the Need for Read More
โHigh Riskโ Patients with Unusual Hormone Receptors May Be Undertreated Read More
CHICAGO โ Molecular subtyping can help predict outcomes and chemotherapy Read More
IRVINE, CA, May 31, 2013 โ Agendia, a world leader Read More
IRVINE, CA, May 2, 2013 โ Agendia, a world leader Read More
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction